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Chaperones are central to the proteostasis network
(PN) and safeguard the proteome from misfolding,
aggregation, and proteotoxicity. We categorized the
human chaperome of 332 genes into network com-
munities using function, localization, interactome,
and expression data sets. During human brain aging,
expression of 32% of the chaperome, correspon-
ding to ATP-dependent chaperone machines, is
repressed, whereas 19.5%, corresponding to ATP-
independent chaperones and co-chaperones, are
induced. These repression and induction clusters
are enhanced in the brains of those with Alzheimer’s,
Huntington’s, or Parkinson’s disease. Functional
properties of the chaperome were assessed by
perturbation inC. elegans and human cell models ex-
pressing Ab, polyglutamine, and Huntingtin. Of 219
C. elegans orthologs, knockdown of 16 enhanced
both Ab and polyQ-associated toxicity. These corre-
spond to 28 human orthologs, of which 52%and 41%
are repressed, respectively, in brain aging and dis-
ease and 37.5% affected Huntingtin aggregation in
human cells. These results identify a critical chaper-
ome subnetwork that functions in aging and disease.INTRODUCTION
The proteomes of eukaryotic cells and tissues are represented
by a collection of structurally and functionally diverse proteins
that form protein-protein interaction networks to communicate
within and between cells and tissues to achieve cellular health-
span and organismal lifespan (Gavin et al., 2006). Protein quality
control mechanisms such as the proteostasis network (PN) pro-
tect proteome functionality and prevent accumulation of mutant,
misfolded, and damaged proteins (Balch et al., 2008). Protein
aggregation has profound consequences on cellular and organ-Cell Rismal health and can cause both gain of function and loss of
function (Park et al., 2013; Yu et al., 2014).
Protein conformational diseases are widespread and include
cancer and metabolic and neurodegenerative disorders (Haass
and Selkoe, 2007; Powers et al., 2009; Xu et al., 2011). Whereas
pathogenic pathways for neurodegenerative diseases such as
Alzheimer’s (AD), Huntington’s (HD), and Parkinson’s (PD) inter-
sect (Ehrnhoefer et al., 2011), the clinical profiles and environ-
mental and genetic risk factors vary substantially (Langbehn
et al., 2004; Belin and Westerlund, 2008; Hampel et al., 2010).
For neurodegenerative diseases, the most significant and uni-
versal risk factor is aging; moreover, evidence suggests a mech-
anistic link between aging, aggregation-mediated proteotoxicity,
and loss of proteostasis, which has been put forth as one of the
nine hallmarks of aging (Cohen et al., 2006; Lo´pez-Otı´n et al.,
2013). The accumulation of proteotoxic species during aging is
inversely correlated with age-associated proteostasis decline
(Ben-Zvi et al., 2009). Chronic expression of misfolded proteins
in age-onset neurodegenerative disease leads to accumulation
of misfolded species and aggregates that overwhelm proteosta-
sis as a basis of cellular dysfunction (Gidalevitz et al., 2006;
Douglas and Dillin, 2010).
A central component of the PN is molecular chaperones and
co-chaperones that determine the cellular folding environment,
prevent misfolding, and redirect nonnative intermediates to
the native state (Hartl et al., 2011) or for clearance by the ubiqui-
tin-proteasome system and autophagy (Schmidt and Finley,
2014). The ‘‘chaperome’’ corresponds to the ensemble of chap-
erones and co-chaperones that interact in a complex network
of molecular folding machines to regulate proteome function
(Albane`se et al., 2006). An understanding of the chaperome will
be instrumental to the biology of aging and how loss of proteo-
static control increases the risk for protein conformational dis-
eases. Whereas much is known about the function of individual
chaperones (Hartl et al., 2011), there is only a limited analysis
of chaperome dynamics and connectivity in metazoans. We
therefore compiled the human and C. elegans chaperome by a
systematic literature search as a basis for integration of human
protein-protein interactions (PPIs) and aging brain expression
data to achieve a chaperome interactome network. This waseports 9, 1135–1150, November 6, 2014 ª2014 The Authors 1135
complemented by functional chaperome-wide RNAi screens in
C. elegans models of Ab and polyQ proteotoxicity and a human
cellular model of Huntingtin aggregation.
Our study has identified chaperone clusters that exhibit strik-
ing repression and induction expression patterns in human brain
aging. Repression predominates and involves all major families
of cytosolic chaperones with a preponderance of ATP-depen-
dent chaperones. We observed concordance of these dynamics
with expression in brain tissues of AD, HD, and PD patients. The
correlation of these dynamics underlines the central role of the
chaperome in aging and disease. The complement of informatics
with experimentation identified a chaperome subnetwork that
safeguards cellular and organismal proteostasis in C. elegans
models and human tissue culture cells expressing neurodegen-
erative disease-related misfolded proteins. This emergence of a
conserved chaperome subnetwork provides a resource for
future studies to establish how changes in the PN affect aging
and disease.
RESULTS
Composition of the Human Chaperome
We examined the expression of genes encoding molecular
chaperones in human brains during normal aging and in neuro-
degenerative disease. For this, we compiled a list of all human
chaperones and co-chaperones by combining the extensive
literature on the biochemical properties of molecular chaperones
together with curation and structural genomics profiling tomatch
genes by InterPro protein domain identifiers (IPR-IDs) (Hunter
et al., 2012; Figure 1A; Table S1). This analysis identified 332
genes (Figure 1A; Tables S1 and S2A; Supplemental Experi-
mental Procedures) that were unambiguously placed into nine
chaperone gene families, corresponding to heat shock protein
90 (HSP90), HSP70, HSP60, HSP40, prefoldin, small HSPs
(sHSPs), tetratricopeptide repeat (TPR)-domain-containing
(Hartl and Hayer-Hartl, 2002), and organellar-specific chaper-
ones of the ER (Kleizen and Braakman, 2004) and mitochondria
(MITO) (Tatsuta et al., 2005). For genes with matching IPR-
criteria domains, the groupings were prioritized by chaperone
properties rather than localization. The organellar categorization
of ER or MITO specific represents chaperones for which the
biochemical, genetic, and cell biological evidence supports
both chaperone function and organellar-specific localization
and for which no IPR domain match could be obtained.
Of the 332 genes that comprise the human chaperome, 88
are functionally classified as chaperones and 244 are co-cha-
perones. Among the 88 chaperones are 50 ATP-dependent
chaperone genes and 38 ATP-independent chaperones. The
ATP-dependent chaperones are comprised of the 5 HSP90s,
17 HSP70s, 14 HSP60s, 6 ER-specific, and 8 MITO-specific
Hsp100/AAA+ ATPases, respectively. In the HSP70 family are
the 17 holding and folding ATP-dependent HSP70s and ten
ATP-independent co-chaperones, corresponding to the nucleo-
tide exchange factors (NEFs) BAG1–BAG6, the GrpE NEFs
GRPE1 and GRPE2, SIL1 (Hsp110/BAP), and HSPBP1 (Mayer,
2013). Likewise, the HSP90 family is comprised of 46 members
including the five ATP-dependent HSP90 chaperones (Pearl
and Prodromou, 2006) and 41 ATP-independent co-chaperones1136 Cell Reports 9, 1135–1150, November 6, 2014 ª2014 The Auththat regulate HSP90 including the two AHA1 co-chaperones
(AHSA1 and AHSA2), CDC37, CDC37L1, p23, and 36 immu-
nophilins subclassified into 18 cyclophilins and 18 FKBPs. The
49 HSP40s correspond to a separate family of ATP-independent
co-chaperones that function as holding chaperones and HSP70
co-chaperones. Taken together, the HSP90, HSP70, and HSP60
chaperone systems correspond to 26.5% of the chaperome,
with the HSP40s contributing another 15% to the chaperome.
Among the 38 ATP-independent chaperone genes are ten
sHSPs, nine prefoldins, four MITO-specific, and 15 ER-specific
chaperones. Another 19% of the chaperome are represented
by the 48 ER-specific and 14 MITO-specific chaperones (Fig-
ure 1A; Table S2A) including 26 ER-specific oxidoreductases
and two MITO-specific protein-disulfide-isomerase-type thiore-
doxins. Notably, the largest chaperome subclass is the 114 TPR
domain-containing genes, representing 34% of the chaperome.
These include STIP1 (HOP) that functions as an HSP70 and
HSP90 co-chaperone (Prodromou et al., 1999; Song and Masi-
son, 2005) and contains three TPR-classifier IPR domains
(IPR001440, IPR013026, and IPR019734). Although many of
these newly identified members of the TPR-domain family
have not been yet shown to function as HSP70 and HSP90
co-chaperones, we opted for a comprehensive and inclusive
approach. Some of thesemembers have been recently validated
in C. elegans using biochemical assays (Haslbeck et al., 2013).
This organization into nine functional families lends itself to a sys-
tems-level evaluation of chaperome functionality in aging and
disease.
Differential ChaperomeDynamics in Human Brain Aging
Weexamined the dynamics of the human chaperome using gene
expression data from the superior frontal gyrus (SFG) of 48
brains from neuropathologically and neurologically normal con-
trol individuals of 20–99 years (Berchtold et al., 2008; Loerch
et al., 2008). Analysis of the expression patterns of the human
chaperome (Figure 1B) revealed a profile that correlated with ag-
ing (p = 6.863 106) and clustered into two groups with a mean
age of 36 ± 4 years and 73 ± 4 years (Figures 1B and 1C). These
age groups are highly pronounced upon hierarchical clustering
but are discernable even when ordered by chronological age
(Figure S1A).
Aging correlation analysis of the human chaperome expressed
in the SFG identified 101 chaperone genes (31.8%) that are
repressed (corrage < 0 and p < 0.05), and 62 (19.5%) genes that
are induced during aging (corrage > 0 and p < 0.05; Figure 1B;
Table S3). Chaperome age expression revealed enrichment of
certain functional families in induction and repression clusters
(Figures 1B and S3A–S3D). TPR proteins tend to be induced,
whereas HSP40s are repressed (Figure 1B). The significance of
the repression and induction clusters is further supported by
analysis of an independent data set from frontal lobes of individ-
uals of 24–40 years and 70–94 years (Loerch et al., 2008; Fig-
ure S1D). Clustering identified isochronal aging repression and
induction clusters with a significant boundary between the two
age groups (Figures 1B, 1C, S1A, and S1B). Analysis of both
data sets revealed that the chaperome genes repressed and
induced in bothdata sets of normal brain agingoverlapped signif-
icantly (p < 2.23 1016 and p = 1.73 1012, respectively; Figuresors
Figure 1. Differential Chaperome Responses in Human Brain Aging and Neurodegenerative Disease
(A) The human chaperome. Functional families and number of members are indicated.
(B) Heatmap showing 318 chaperones expressed in human brain (super frontal gyrus) ordered by decreasing age correlation. Thewhite dashed line indicates age-
expression correlation coefficient closest to zero. Genes above the red line are induced (p < 0.05); genes below the green line are repressed (p < 0.05). The
histogram visualizes specimen age upon hierarchical clustering. The dendrogram visualizes hierarchical clustering of brain specimens. The y axis color code
highlights from left to right the nine chaperome families, chaperones (black), co-chaperone (gray), and ATP-dependent chaperones (turquoise).
(C) Three major age groups (blue, ‘‘young’’; orange, ‘‘transition’’; green, ‘‘old’’) are visualized by dendrogram coloring in (B). Values are mean age ± SEM. ***p <
0.001; Student’s t test.
(D) Overlaps of chaperones induced (red) or repressed (green) in aging versus AD.
See Figures S1–S3.
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S1E and S1F). We observed similar age clusters with significant
boundaries in entorhinal cortex (Figure S1C), confirming chap-
erone expression dynamics in brain aging in different data sets.
Concordant Dynamics of Chaperome Expression in
Brain Aging and Neurodegenerative Diseases
Because aging represents a risk factor for neurodegenerative
disease, we assessed the impact of AD, HD, and PD on chaper-
ome dynamics by examining expression in patient brain samples
(Hodges et al., 2006; Moran et al., 2006; Liang et al., 2008; Table
S3C–S3E). When analyzing brain-expression data sets from
AD patients, we identified 101 significantly repressed genes
and 34 induced genes compared to age-matched controls.
Both in aging and AD brains, chaperome repression is signifi-
cantly enriched compared to overall gene repression in the
genome (Figures S2A and S2B). We then asked whether the
chaperome genes differentially regulated in AD overlapped
with the aging-regulated chaperome genes and identified 21
genes that overlapped between the 62 genes induced in aging
and 34 genes induced in AD (p = 7.89 3 109) and 58 genes
that overlapped between 101 aging-repressed and 101 AD-
repressed chaperone genes (p = 7.63 1011; Figure 1D). Among
the genes that are repressed in both aging and AD, the HSP70-
HSP40 system corresponds to 36% of the 58 genes (Table S3D).
Chaperome genes consistently repressed in aging and AD
include members of all nine functional chaperome families,
revealing that alterations in chaperone expression are not selec-
tive to specific gene families. The 21 genes induced in both aging
and AD extend across all functional families except HSP60
genes. Similarly, we also examined whether the chaperome
genes regulated in aging overlapped with those dynamically
regulated in HD and PD. Among the 245 chaperome genes de-
tected in all data sets, 36 genes overlapped between genes
repressed in aging and HD (p = 3.96 3 107) and 24 genes be-
tween aging and PD (p = 0.01062; Figures S2C and S2E). Chap-
erome genes induced in aging also significantly overlapped with
genes induced in HD (p = 2.943 1010) and PD (p = 0.00059; Fig-
ures S2D and S2F; Table S3).
We partitioned the chaperome age-expression distribution
into the nine families and observed reproducible expression pat-
terns in four distinct brain tissues (Figures S3A–S3D). Ranked by
decreasing median aging correlation, the induction of sHSPs
and TPR genes consistently ranked high and the HSP60s,
HSP40s, and HSP70s were consistently repressed. Among
repressed genes, the HSP40s exhibited significant change (p =
0.04875), with 62% of 48 HSP40 genes repressed in aging (p <
0.05) and 51% repressed in AD. Of these, 41% are repressedFigure 2. Chaperome Network Community Dynamics in Brain Aging an
(A) Integrated human chaperome network based on physical protein-protein intera
concordantly induced or repressed during brain aging. PPIs (solid edges). COX
between age and gene expression. Link communities highlighted by edge color;
(B) Heatmaps visualize induction or repression in aging, AD, HD, and PD at node
names are indicated. Color code micrographic visualizes functional family. Signi
respectively, and nonsignificantly induced and repressed genes with pR 0.05 a
(C) Chaperones and co-chaperones selected from induction and repression comm
average expression ± SEM. Values indicated inside the bars indicate ratios of ex
test.
Cell Rin both aging (SFG) and AD (p = 0.0009). Among the genes
that are induced in brain aging and disease are sHSPs and
TPR-containing chaperone genes (Figures S3A–S3D).
The distribution of ATP-dependent chaperones in aging and
AD was shown to be enriched 10-fold in the repression cluster
of aging SFG (p = 4.83 106) and 11-fold in the prefrontal cortex
(PFC) (p = 1.7 3 107; Figure S3E) whereas ATP-independent
chaperones exhibited equivalent levels of repression and induc-
tion. This analysis of the chaperome in human brain aging also
reveals concordant exacerbation of responses in neurodegener-
ative disease. These concordant chaperome changes provide
evidence for significant changes in the proteostasis network in
aging and neurodegenerative disease.
Chaperome Network Community Dynamics in Brain
Aging and Disease
The repression and induction of chaperones in brain aging likely
affect the cellular balance of chaperone machines and function-
ality of the PN, leading us to consider how these components of
the chaperome are physically and functionally associated. We
visualized the systems-level connectivity of the chaperome by
integrating physical protein-protein interactions (PPI edges)
from public databases together with coexpression pairs in aging
brains (COX edges; Tables S4 and S5) into a PPI-COX interac-
tome (Figure 2A). The COX edges were identified using trans-
criptome data from SFG tissue given its highly significant and
pronounced aging dynamics. Among all 50,403 chaperome
pairs, we found 1,193 significant COX edges (corrage > 0.8 and
p < 0.05), of which 15 of 191 unique PPIs are also COX edges.
Applying the link-community-clustering algorithm (Ahn et al.,
2010) to the PPI-COX network, we identified 40 link commu-
nities, of which 34 are repression communities compared to
only six induction communities (Figure 2A; Table S6).
This network community-clustering analysis also revealed that
themajority of genes residing in induction or repression link com-
munities showed concordant patterns in aging and neurodegen-
erative diseases, respectively (Figures 2A and 2B), leading to the
hypothesis that these aging-expression changes can affect
the cellular balance of chaperone machines and functionality of
the PN. For example, concordantly aggravated expression pat-
terns for the aging-induced genes HSPA2 (HSP70) and DNAJB2
(HSP40) and the aging-repressed HSPA12A (HSP70) and
TOMM70A (TPR) were observed in brain biopsies from AD,
HD, and PD patients (Figure 2C). In terms of gene-expression
dynamics in aging and disease, these exemplary genes are
representative for induction and repression cluster dynamics.
Included in the repression cluster are members across eight ofd Age-Onset Neurodegenerative Diseases
ction (PPI) and coexpression (COX) edges and link communities of chaperones
> 0.8 (dashed edges). Color scale indicates positive to negative correlation
yellow node borders indicate significant age-expression correlation (p < 0.05).
resolution for communities highlighted in (A). Community numbers and gene
ficantly induced and repressed genes (p < 0.05) shown in dark red and green,
re shown in light red and light green. See Figures S2 and S3.
unities and their expression in brains from AD, HD, and PD patients. Values are
pression in disease over control. *p < 0.05; **p < 0.01; ***p < 0.001; Student’s t
eports 9, 1135–1150, November 6, 2014 ª2014 The Authors 1139
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nine chaperone gene families with predominance of ATP-depen-
dent chaperones and HSP40 co-chaperones, whereas induction
communities are enriched for TPR-domain co-chaperones and
sHSPs. These observations provide support that prominent
changes in chaperone expression levels could accelerate AD,
HD, or PD disease pathology characterized by elevated toxic
gain-of-function aggregation. Chaperome repression commu-
nities dominate the network landscape in human brain aging
and disease, linking known chaperones and co-chaperones
with less well-characterized chaperones, possibly revealing
novel interactions important for the aging and disease PN.
Chaperome Function in C. elegans Models of Protein
Aggregation
To complement the bioinformatics analysis of the human chap-
erome with in vivo functional data, we experimentally validated
the functional consequences of repressed chaperome gene
expression and function during aging and disease using two es-
tablished C. elegans models expressing the cytotoxic aggrega-
tion-prone proteins, Ab (Ab42) and polyQ (Q35), implicated in
AD and polyglutamine (HD) diseases, respectively (Link, 1995;
Satyal et al., 2000; Morley et al., 2002). In both models, aggrega-
tion and toxicity, measured by decreased motility, increases in
an age-dependent manner and can be suppressed by lifespan-
enhancing pathways such as the insulin-like signaling pathway
(daf-2 and age-1) and the heat shock response (hsf-1; Morley
et al., 2002; Cohen et al., 2006). We assembled and curated
theC. elegans chaperome by orthologymapping andmanual cu-
ration (Harris et al., 2010; Sayers et al., 2012; see Supplemental
Experimental Procedures) and identified 219 C. elegans chap-
erone and co-chaperone genes, corresponding to the same
nine functional gene families (Table S2B). Comparison of
C. elegans and human chaperomes revealed similar proportions
of most functional families, with notably a reduction in TPR
domain co-chaperones to 24% of the C. elegans chaperome
from 34% in the human chaperome and increased number of
sHSPs to 19 genes inC. elegans from ten sHSP genes in humans
(Figure 3A).
We first examined the functional requirements of all 219
C. elegans chaperome genes using RNAi knockdown in animals
expressing Ab42 by monitoring early-onset paralysis on day 4 of
adulthood (Figure 3B). Based on our methodology of screening,
assessing age-dependent aggregation and toxicity phenotypes
(measured by decreased motility), genes when knocked downFigure 3. Functional Chaperome Perturbation Analyses in C. elegans M
(A) The C. elegans chaperome with its functional families and numbers of memb
(B) Paralysis (%motility) for wild-type and Ab42-expressing C. elegans from day 1
average percent motility ± SEM (n = 3 and nR 25 animals/trial). **p < 0.01; Stud
(C) Motility defects for wild-type and Q35-expressing C. elegans from day 1 to d
(D) RNAi paralysis phenotypes on day 4 of adulthood (%motility) forC. elegans ex
percent motility ± SEM (n = 3 and nR 25 animals/trial).
(E) RNAi motility defects on day 2 of adulthood (% motility) for C. elegans expres
(F) Venn diagram indicating significant overlap of 16 hits from both screens (p <
(G) Average paralysis (% motility) for RNAi of all 16 chaperome subset genes in A
averages of corresponding data points in each RNAi experiment ± SEM, each b
Student’s t test.
(H) Average paralysis (% motility) for chaperome subset RNAi in Q35-expressing
See Figure S4.
Cell Rthat caused motility defects in both wild-type and disease
models were eliminated; in other words, genes that gave the
same magnitude of phenotypic change in wild-type animals
were not further considered. This functional screen identified
18 genes (Figure 3D), corresponding to ten ATP-dependent
chaperones, HSC70 (hsp-1), HSP90 (daf-21), and eight subunits
of the CCT/TRiC chaperonin complex; the co-chaperones,
HSP40 (dnj-12) and CDC37 (cdc-37); and the TPR-domain pro-
tein STI1 that upon knockdown significantly enhanced Ab42 pro-
teotoxicity (Figure 3D). Included among these modifiers were
four TPR-domain proteins; the anaphase-promoting complex
(APC/C) subunitsmat-1,mat-3, and emb-27; and the uncharac-
terized open reading frames, Y39A3CR.3 (tpr-1) and Y57G7A.10
(tpr-2), conserved in human as TTC7A/TTC7B and EMC2, with a
phenotype on the Ab42 animals that were not previously impli-
cated in proteostasis.
To test whether the chaperone genes that regulate Ab42
proteotoxicity have more general effects, we performed a
subsequent RNAi screen using a C. elegans model for expres-
sion of aggregation-prone polyQ (Q35), associated with HD
pathogenesis. This model of chronic Q35 protein expression
and aggregation exhibits an early-onset, age-dependent dec-
line in muscle function (Figure 3C; Morley et al., 2002). Knock-
down of 21 of the 219 C. elegans chaperome genes signifi-
cantly enhanced polyQ-dependent proteotoxicity (Figure 3E).
These correspond to the same ATP-dependent chaperones
(daf-21, hsp-1, and the eight CCT/TRiC complex subunits)
that overlapped with the Ab42 screen and 11 co-chaperones,
of which six genes were identified in both screens, including
the TPR-domain APC/C subunits mat-1 and emb-27 and the
TPR protein, Y39A3CR.3 (tpr-1; Figures 3D and 3E). These re-
sults reveal an overlapping common subset of 16 chaperome
genes including the newly identified members of the APC/C
(p < 2.2 3 1016; Fisher’s exact test; Figures 3D–3F). Addi-
tionally, these screens also identified seven chaperones with
more selective phenotypes on either Ab42- or Q35-expressing
animals.
To investigate whether the common chaperome subset also
affects age-related proteotoxicity, we assessed the functionality
ofC. elegansmuscle throughout adulthood (days 1–12) following
RNAi knockdown of all 16 subset genes in both models. All 16
genes were highly protective in the Ab42 (p = 0.0012) and Q35
models (p = 0.0097) and showed significant reduction in motility
upon RNAi, suggesting that repression of the chaperome subsetodels of Protein Misfolding
ers per family are shown.
to day 12 of adulthood. Arrow indicates paralysis age of onset. Data points are
ent’s t test.
ay 12. Arrow indicates age of onset. Data points as in (B).
pressing Ab42 (mean ± SEM; n = 3 and nR 25 animals/trial). Values are average
sing Q35 (mean ± SEM; n = 3 and nR 25 animals/trial). Values as in (D).
2.2 3 1016; Fisher’s exact test).
b42-expressing C. elegans throughout adulthood (days 1–12). Data points are
ased on nR 3 independent experiments and nR 25 animals/trial. **p < 0.01;
C. elegans throughout adulthood (days 1–12). Data points as in (G).
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renders aged organisms more susceptible to proteotoxicity (Fig-
ures 3G, 3H, and S4).
A Chaperome Subset Safeguards Proteostasis in
Aging C. elegans
Our network analysis of chaperome repression demonstrated
concordant changes in brain aging and neurodegenerative
disease (Figures 1D and S2). This led us to speculate whether
expression of these chaperones also changes during aging,
thus affecting the susceptibility of Ab42- and Q35-expressing
animals to proteotoxic insult (Figures 3G and 3H). To address
this, we monitored the age-dependent changes in motility of
C. elegans that express a metastable temperature-sensitive mu-
tation in paramyosin (UNC-15TS) that misfolds in early adulthood
at the permissive temperature (Gidalevitz et al., 2006). At the
permissive temperature, knockdown of the chaperome subset
(Figures 4A and S4C) substantially exacerbated the loss of mus-
cle cell function during aging of UNC-15TS animals, providing
direct functional evidence for a protective role in aging.
To further characterize the chaperome subset during aging,
we monitored various physiological phenotypes in wild-type
and RNAi-treated animals and showed that this subset of the
chaperome is important to prevent or delay age-dependent pa-
ralysis (Figures 4B, 4C, and S4D). Knockdown of daf-21 (HSP90)
or hsp-1 (HSC70) led to increased paralysis in 45% and 44% of
day 6 animals, respectively, and knockdown of TPR co-chaper-
ones tpr-1 and dnj-12 resulted in 70% impairment (Figure S4D).
The loss of motility in wild-type animals was due to deterioration
of myofilament structure (sarcopenia). We monitored the in-
tegrity of MYO-3, a heavy chain component of myofilaments
by MYO-3::GFP fluorescence and, upon knockdown of dnj-12
and emb-27, observed more-severe sarcopenia at day 8 com-
pared to day 1, whereas structural integrity of muscle was
maintained up to day 8 in controls (Figure 4D). Consistent with
these observations, RNAi of cct-1, hsp-1, and daf-21 leads to
premature Q35 aggregation (Figure 4E), recapitulating the mis-
folding of disease-associated polyQ proteins, a hallmark of
HD. Our evidence at cellular and organismal levels suggests
that the chaperome subset safeguards proteostasis during
aging.
The Chaperome Subset Safeguards Proteostasis
in Human Cells
To test whether the chaperome subset identified in C. elegans
models of Ab and Q35 proteotoxicity functionally extends to
the human chaperome, and to test its potential contribution to
HD, we used a high-content imaging assay to quantify aggrega-
tion of doxycycline-inducible Huntingtin-exon1(Q78)-GFP (Htt-
GFP) expressed in HeLa cells. The 16 subset C. elegans chaper-
ones and co-chaperones correspond to 28 genes in the human
genome, of which 24 genes are expressed in HeLa cells (Nagaraj
et al., 2011; Figure 5A). We confirmed small interfering RNA
(siRNA) knockdown efficiency of HTT-GFP, CCT2, DNAJA1,
and HSPA8 by immunoblot analysis to show reduced levels of
these chaperones (Figure S5A). An increase in the fraction of
Htt-GFP-expressing cells with protein aggregates was observed
upon knockdown of 15 human chaperones compared to control,
corresponding to 63% of the human chaperome subset and1142 Cell Reports 9, 1135–1150, November 6, 2014 ª2014 The Auth75% of the worm chaperome subset, respectively (Figure 5B;
Table S7). These included all subunits of the CCT/TRiC complex
(except CCT5); HSP40 and HSP70 family members DNAJA1
(HDJ-2), DNAJA4, HSPA8 (HSC70), and HSPA14 (Figures 5B
and 5C); and the TPR-domain APC/C subunits CDC23 and
CDC27 that, upon knockdown, led to significantly elevated
aggregation (Figure S5B). The overall protective effect of the
chaperome subset in human cells against Htt-GFP aggregation
provides additional functional evidence to support the results
from the C. elegans RNAi analysis of the chaperome subset in
proteotoxicity.
The Chaperome Subnetwork Is Repressed in Brain
Aging and Disease
Whereas broad chaperome repression in aging human brains
pointed toward proteostasis functional decline and increased
susceptibility to proteotoxic insults in neurodegenerative dis-
eases, our functional screens in C. elegans led to the identi-
fication of a common chaperome subset. To investigate the
dynamics of the corresponding chaperome subset in human
brain aging and disease, we examined the connectivity of the
chaperome interactome and partitioning across communities
of induction and repression. We matched orthologous human
chaperome subset nodes in the PPI-COX chaperome interac-
tome to visualize their expression dynamics and interactome
topology (Figure 6A). Of the 28 human nodes, 27 genes are ex-
pressed in the human brain (Berchtold et al., 2008), of which the
majority (20 genes) are interconnected in a major component
involving 60 edges. This human chaperome subnetwork is
significantly interconnected (p < 0.01; Figures 6A and S6A–
S6C). The subnetwork nodes include five chaperone families
and have a higher degree of connectivity than nonsubnetwork
nodes (p = 0.04; Figure S6D). Overall, 52% of subnetwork no-
des are repressed in aging brain compared to 30% repression
of nonsubnetwork nodes (p = 0.0292; Fisher’s exact test; Fig-
ure 6C). Likewise, 52% of subnetwork nodes are significantly
repressed in AD compared to 30% repression of nonsubnet-
work nodes (p = 0.0292; Fisher’s exact test), 24% in HD, and
16% in both diseases (Figure 6C). The chaperome subnetwork
is nearly 2-fold more repressed in brain aging and AD as
opposed to nonsubnetwork chaperome genes. We further
tested the significance of the overlaps of subnetwork genes
repressed in all conditions, aging, AD, and HD as compared
to nonsubnetwork genes, asking whether the subset of chaper-
ome subnetwork genes repressed in both AD and HD is signif-
icantly enriched. Four genes that are significantly repressed
both in AD and HD (HSP90AB1, HSPA8, HSPA14, and TCP1)
are also repressed in aging (Figure 6B). We applied a Fisher
exact test considering all chaperome genes significantly
repressed in at least one condition, AD, HD, or aging, which in-
cludes 19 chaperome subnetwork and 142 nonsubnetwork
chaperome genes. The significance of the observation that a
set of four genes repressed in AD and HD is also repressed in
aging (p < 10 3 105; Fisher’s exact test; Figure 6D) demon-
strates the power of integrating data from more than one dis-
ease and aging. Some of the subnetwork chaperome nodes
that were not significantly repressed in aging are repressed in
AD, including the APC/C complex TPR-domain subunitsors
Figure 4. A Chaperome Subset Safeguards C. elegans Pro-
teostasis against Aging-Related Proteotoxicity
(A) Average paralysis (% motility) for chaperome subset RNAi in the
unc-15(e1402) TS strain at 15C throughout adulthood (days 1–12).
Data points are averages of corresponding data points in each RNAi
experiment ± SEM, based on nR 3 experiments and nR 20 animals/
trial. **p < 0.01; Student’s t test.
(B) Average paralysis (% motility) in aged wild-type animals
throughout adulthood (days 1–12). Data points as in (A).
(C) Early-onset paralysis (% motility) upon chaperome subset RNAi in
aged wild-type animals (compare B) as area under the curve (AUC) for
control aging wild-type worms (average ± SEM; n = 5) and average of
RNAi-treated aging wild-type worms (average of 16 subset pheno-
types ± SEM, each n = 3). **p < 0.01; Student’s t test.
(D) Sarcopenia phenotype upon control, dnj-12, and emb-27 RNAi
visualized by MYO3::GFP fluorescence at day 1 versus day 8 of
adulthood. The scale bar represents 10 mm.
(E) Early-onset aggregation of polyQ (Q35) expressed in body wall
muscle cells upon chaperome subset RNAi. Q25, subthreshold polyQ.
Graph shows increased average aggregate count upon RNAi
compared to control ± SEM (n R 100 animals; n = 3). The scale bar
represents 0.02 mm.
See Figure S4.
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Figure 5. Human Chaperome Subnetwork Safeguards Proteostasis against Huntingtin Aggregation
(A) Sixteen chaperome subset members identified by RNAi screens in Ab42 and Q35 C. elegans models grouped by functional family. APC/C, anaphase-pro-
moting complex/cyclosome and the corresponding 24 human chaperome subset members identified by orthology mapping.
(B) Percentage of HeLa cells with greater than or equal to one Huntingtin-exon1(Q78)-GFP (HTT-GFP) aggregate and upon siRNA. Results shown for all 24 human
orthologs expressed in HeLa, corresponding to the 16 C. elegans chaperome subset members. Values are averages ± SEM (n = 6). Red, gray, and green bars
represent increased, unchanged, and decreased aggregation, respectively, measured as ‘‘%CellsR 1 aggregate’’. *p < 0.05; **p < 0.01; ***p < 0.001; Student’s t
test.
(C) Representative images for nontargeting (NT) siRNA, siRNA-GFP (positive control), and siRNA against each one member of the chaperome subset functional
families are shown. Red arrows exemplify HTT-GFP aggregates. The scale bar represents 20 mm.
See Figure S5.
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Figure 6. The Human Chaperome Subnetwork Is Repressed in Aging and Disease
(A) Extraction of the human orthologous chaperome subnetwork from the chaperome interactome shown in Figure 2A to highlight chaperome subnetwork
dynamics in human aging brain and neurodegenerative disease. Nodes, edges, shapes, and edge strengths as in Figure 2A.
(B) Human chaperome subnetwork superimposed on Venn overlaps of chaperome genes significantly repressed in aging, AD, and HD.
(C) Graphs show percent subnetwork (sub-net) versus percent nonsubnetwork (non sub-net) chaperome nodes repressed in human aging brain (SFG) and brains
from Alzheimer’s (SFG) and Huntington’s disease (PFC) patients (see Figure S6). SFG, superior frontal gyrus; PFC, prefrontal cortex.
(D) Venn diagram of overlaps of chaperome subnetwork genes significantly repressed in both AD and HD as well as in aging. p values are based on Fisher’s exact
test, considering only chaperones that are significantly repressed in at least one of the three conditions: aging, AD, or HD. The blue overlap area and p value
indicate the significance of the overlap of subnetwork genes repressed in all three conditions against the union of subnetwork genes repressed in ‘‘aging only’’
and in ‘‘aging and AD’’; the red overlap area and p value indicate the significance of the overlap of subnetwork genes repressed in all three conditions against the
union of subnetwork genes repressed in aging only and in ‘‘aging and HD’’.CDC16 and CDC27. These results reveal that the chaperome
subnetwork is significantly more interconnected in the human
interactome and concordantly more repressed in brain aging.Cell RThe significantly enriched fraction of aging-repressed subnet-
work chaperome nodes versus nonsubnetwork nodes and their
aggravated repression in aging and disease is in agreement witheports 9, 1135–1150, November 6, 2014 ª2014 The Authors 1145
the chaperome subnetwork phenotypes observed in our RNAi
functional perturbation experiments.
Thus, our orthogonally integrated chaperome-scale approach
successfully identified a small subset of chaperones and specific
co-chaperones from hundreds of chaperone and co-chaperone
factors, including well-established and novel regulators of pro-
teostasis maintenance in aging and disease that are highly inter-
connected in a chaperome subnetwork.
DISCUSSION
Molecular chaperones, being among the most highly conserved
genes with essential functions for protein biogenesis, might have
been thought to be equally important for proteomemaintenance.
Our analysis of chaperome dynamics combines the analysis of
expression in human brain and neurodegenerative disease,
experimental validation using C. elegans and human cells ex-
pressing disease-associated aggregates, and protein-protein
interaction network analysis, from which we have identified a
chaperome subnetwork affected in aging and disease. This
study has identified a subset of the chaperome that is critical
to maintain proteostasis in aging and upon challenge with neuro-
degenerative disease-associated proteins. This combined ap-
proach led to identification of a conserved subset of 16 genes
in C. elegans, comprised of the ATP-dependent chaperones
HSC70 and HSP90; the CCT/TRiC complex; and select HSP40
and TPR-domain co-chaperones that exhibit altered expression
during human brain aging and are functionally required in
C. elegans models to prevent proteotoxicity of neurodegenera-
tive-disease-associated proteins. Of the human chaperome of
332 genes, 32% are repressed in brain aging, corresponding
mostly to ATP-dependent chaperone machines involved in
holding intermediates and folding to the native states, and are
represented by highly connected repression clusters that
concordantly decline in brains of AD, PD, and HD patients. We
propose that changes in expression of the subnetwork may
signify early events, leading to age-associated proteostasis
collapse with implications for the pathogenesis of neurodegen-
erative disease.
The composition of the chaperome subnetwork highlights the
central importance of specific ATP-dependent cytoplasmic
chaperone machines during aging from C. elegans to human
essential to achieve a healthy-tissue proteostatic state that can
withstand challenge by expression of cytoplasmic polyQ expan-
sion proteins or Ab. Some of these chaperones such as the
HSP70-HSP40 machine have been previously implicated in the
modulation of polyQ-expanded protein aggregation (Cummings
et al., 1998; Jana et al., 2000). Likewise, the level of cytosolic
chaperonin affects polyQ toxicity by actively modulating the ag-
gregation state, a major cause of polyQ cytotoxicity in Hunting-
ton’s disease (Nollen et al., 2004; Behrends et al., 2006; Kitamura
et al., 2006; Tam et al., 2006). Differences are revealed that may
point toward aging or disease-specific subnetwork modules or
contribution of only parts of the subnetwork to pathways
involved in molecular pathology of these diseases. Notably,
HSP90 resides at the intersection of aging, AD, and HD. The
lower overall number of subnetwork versus nonsubnetwork
genes repressed in HD compared to those repressed in AD could1146 Cell Reports 9, 1135–1150, November 6, 2014 ª2014 The Authcorrespond to differences in the molecular underpinnings of
these diseases, whereas the six subnetwork genes significantly
repressed in HD are also significantly repressed in aging,
including HSP90, HSP70, and chaperonin (TCP1), representa-
tive of the core cytoplasmic molecular folding machineries. In
addition to identification of the major ATP-dependent chaper-
ones in our functional screens, we show that components of
the APC, an E3 ubiquitin ligase that targets proteins for degrada-
tion, are highly effective modifiers of Ab and polyQ proteotoxicity
phenotypes. Despite its established role in the exit from mitosis,
it has been shown that the APC is functional in postmitotic neu-
rons (Gieffers et al., 1999; Kim et al., 2009; Marrocco et al., 2009)
with a role in cognitive processes (Kuczera et al., 2011). Further
evidence suggests that deregulated APC function is associated
with neurodegeneration and cognitive decline (Almeida et al.,
2005; Li et al., 2008; Maestre et al., 2008), and a screen in yeast
identified the APC asmodifier of polyQ toxicity (Bocharova et al.,
2008). Considering existing evidence, we propose that these
APC components represent novel proteostasis modifiers with a
role in degradation through their E3 ubiquitin ligase function,
whereas mechanistically, it is possible that they may function
as co-chaperones. Previous studies using RNAi in C. elegans
have identified components acting in protein degradation as
modifiers of polyQ proteotoxicity (Nollen et al., 2004).
The largest chaperome gene class is the 114 TPR-
domain-containing proteins corresponding to 53 orthologs in
C. elegans, accommodating, in an unbiased way, the large de-
gree of functional heterogeneity of TPR-domain proteins in
chaperone-related function. Four C. elegans proteins contribute
to the chaperome subnetwork (sti-1,mat-1, emb-27, and tpr-1),
and another four were identified to affect proteostasis in the Ab
(tpr-2 and mat-3) and polyQ (tpr-3 and tpr-4) models, of which
none except sti-1 had been previously described to have a role
in proteostasis. The TPR family contains the largest number of
members that have not yet been shown to function as HSP90
and HSP70 co-chaperones, although a recent biochemical anal-
ysis in C. elegans identified 13 TPR proteins that interact with
HSP70 or HSP90 (Haslbeck et al., 2013). Based on our inclusive
and unbiased chaperome-scale in vivo results from two indepen-
dent screens, we identified additional TPR-domain proteins to
be functionally equivalent to HSP90 or HSC70, leading us to pro-
pose that these factors harbor properties that are highly linked to
proteostasis network maintenance and concordantly regulated
with global chaperome dynamics in aging and disease.
Previous efforts to characterize chaperone networks have
proposed subnetworks that participate in the folding of newly
synthesized proteins and those that interact with preexisting
proteins that become denatured upon acute stress (Albane`se
et al., 2006). Our network analysis combines chaperome-
expression analysis in aging brains with community network
clustering to organize the connectivity dynamics of the human
chaperome network and provides a 3D representation of the
chaperome subnetwork within the context of the complete chap-
erome interactome. The subnetwork nodes are more intercon-
nected and repressed than nonsubnetwork chaperome nodes
and suggests that perturbation of a subnetwork node and
its edges would result in a more severe perturbation of net-
work integrity compared to the more peripheral low-degreeors
Figure 7. The Chaperome Subnetwork as
Proteostasis Safeguard and Its Collapse in
Disease
(A) Chaperome subnetwork action as buffer that
safeguards proteostasis from proteotoxic stress,
facilitating healthy development and aging.
(B) Chaperome subnetwork perturbation entails
proteostasis collapse, exposure to proteotoxicity,
accelerated aging, and age-onset disease.
Perturbation exemplified by loss of edges and
repression of gene expression (green nodes).nonsubnetwork nodes. Accordingly, loss of protective chaper-
ome subnetwork buffering capacity compromises proteostasis
capacity, leading to an increased sensitivity to endogenous
and exogenous stress and disease predisposition (Figure 7).
The HSP90 chaperone has been proposed to have buffering
capacity in its role as a capacitor of morphological variation
and facilitator of evolution. Reduction of HSP90 levels below a
critical threshold exposes cryptic endogenous variants such as
genetic mutations that would otherwise be corrected or sup-
pressed by HSP90 (Rutherford and Lindquist, 1998; Queitsch
et al., 2002). Local fluctuations in the expression of HSP90 in
one tissue are recognized by transcellular chaperone signaling
by the compensatory expression of chaperones in distant tis-
sues to achieve organismal proteostasis (van Oosten-Hawle
et al., 2013). The chaperome subset described here unites
HSP90 and its co-chaperones with several novel and previously
undescribed PN components in a highly interconnected subnet-
work. We propose that the chaperome subnetwork, rather than
individual chaperones, is important for the properties of the PN
in aging and disease and suggest that this subnetwork is a func-
tional ‘‘core chaperome’’ within the global chaperome (Powers
and Balch, 2013). Based on the importance of proteostasis in
health and disease, we suggest that chaperome subnetwork-tar-
geted therapeutic interventions may be beneficial for a large
number of age-related protein-misfolding disorders (Powers
et al., 2009).
EXPERIMENTAL PROCEDURES
Chaperome Gene List Curation, Annotation, and Orthology Mapping
We curated the literature for chaperone and co-chaperone families, covering
all structural and functional categories and subcellular localizations relevant
to chaperone-assisted protein folding, and comprehensively annotated the
human andC. elegans family members.Wematched genes with domain struc-
tures referenced in UniProt, prioritizing 44 bona fide IPR-criteria domains (IPR-
IDs) (Table S1) characteristic of each family to consolidate our literature-basedCell Reports 9, 1135–1150, Nannotation and to identify members not previously
associated with these families. We organized the
genes into nine functional families based on litera-
ture evidence on activities and the IPR-criteria do-
mains. Chaperones with exclusive function in the
ER and MITO compartments for which no IPR
domain could be matched were grouped as
‘‘ER-specific’’ and ‘‘MITO-specific’’. Small co-
chaperone families with unambiguous functional
association with a chaperone were grouped within
the respective chaperone system (family). HSP40
and TPR-domain co-chaperones were organizedin separate families. Human and C. elegans chaperome gene lists were
matched and reconciled using orthology pairs with the National Center for
Biotechnology Information (NCBI) HomoloGene database. The annotations
were recurated based on the WormBase (release WS234) comparative geno-
mics tool that associates C. elegans genes with human orthologs based on
curated and automated predictions by NCBI KOGs, InParanoid, TreeFam, pre-
computed BLAST results, Ensembl COMPARA, and the orthologs matrix proj-
ect (OMA). We applied bipartite mapping to identify orthology pairs and the
respective species-specific chaperome subsets.
Chaperome Expression Correlation Analyses
Expression profiles for 318 human chaperome genes were extracted from two
independent transcriptome data sets of human brain biopsy tissue samples,
covering subjects from a variety of ages (Berchtold et al., 2008; Loerch
et al., 2008). We calculated Pearson correlation between age and each
chaperone’s expression and evaluated significance of correlation (p < 0.05).
Hierarchical clustering was performed to cluster samples by expression profile
similarity. For further details, see Supplemental Experimental Procedures.
Construction of the Integrated Brain-Aging Chaperome Interactome
We retrieved 64,738 unique human PPIs from MINT, BioGRID, HPRD, and
IntACT and extracted the human chaperome interactome. Among these, we
identified PPIs involving chaperome genes expressed in superior frontal gyrus
of aging human brains (Berchtold et al., 2008). Coexpression correlation coef-
ficients (corrage) were calculated for all-by-all gene pairs to identify pairs with
significant Pearson correlation of coexpression. Pairs with corrageR 0.8 (p <
9.0 3 1012) were considered significantly coexpressed (COX) and combined
with PPIs into an integrated PPI-COX network. Visualizations were generated
in Cytoscape v2.8.1 (Smoot et al., 2011).
Chaperome Network Community Clustering
We applied the link-community-network-clustering algorithm gauged at a
community size cutoff of greater than or equal to three nodes and greater
than or equal to two edges (Ahn et al., 2010) to identify communities of inter-
connected aging-coregulated chaperome genes. See Supplemental Experi-
mental Procedures.
C. elegans Strains and Maintenance
C. elegans wild-type Bristol strain N2, Ab42 CL2006 (dvIs2), Q35 AM140
(rmIs132[Punc-54::q35::yfp]), the temperature-sensitive (TS) mutant strainovember 6, 2014 ª2014 The Authors 1147
CB1402 (unc-15(e1402)), and the RW1596 (myo-3(st386);stEx30[myo-
3::GFP;rol-6(su1006)]) strainsweremaintained according to standardmethods
at 20C on nematode growth media with OP50 E. coli (Brenner, 1974).
C. elegans RNAi Screens for Chaperome Modifiers of Protein-
Misfolding-Related Proteotoxicity
Chaperome-wide RNAi screens for enhancement of motility defects in
C. elegans body wall muscle cells were performed using the commercial
RNAi library. Missing or incorrect clones were cloned into L4440 (Kamath
and Ahringer, 2003). Synchronized L1 animals expressing Ab42 or polyQ
were fed bacteria expressing RNAi for each target. In case of lethality or larval
arrest, worms were fed at the L4 stage. Adult worms from age-synchronized
populations were scored for paralysis (Link, 1995; Ab42 screen) on day 4 or
for motility defects (Silva et al., 2011; Q35 screen) on day 2 of adulthood.
RNAi candidates with 20% decrease in movement compared to control in
greater than or equal to three experiments constitute the final set. For aging-
related proteotoxicity, synchronized adult animals fed chaperome subset
RNAi were assayed daily, and nonresponders to prodding were scored as
paralyzed. unc-15(e1402) animals were grown at 15C and assayed daily for
paralysis. To assess myofilament structure, we monitored MYO-3::GFP fluo-
rescence in animals fed bacteria expressing double-stranded RNA against
each target. Images were taken on days 1 and 8 of adulthood using a Zeiss Ax-
iovert 200 microscope. See Supplemental Experimental Procedures.
Human Chaperome Subnetwork Interactome
We extracted 28 human orthologs of the 16 chaperome subset genes as
described. The human chaperome subnetwork was obtained as a subnetwork
of the PPI-COX chaperome interactome. To test significance, we built 100 ran-
domized control PPI-COX networks, keeping number of nodes, edges, and
node degree constant but rewiring edges between nodes and treating PPI
and COX edges separately to conform to the different nature of these interac-
tions. Network figures were generated with Cytoscape.
siRNA-HCI for Modifiers of Huntingtin Aggregation
Chaperome modifiers of Htt-GFP aggregation (percent of cells greater than or
equal to one aggregate) were identified by siRNA perturbation coupled to high-
content imaging (HCI) in HeLa cells. Monoclonal doxycycline-inducible cells
expressing Htt-GFP were transfected with nontargeting or quadruplex siRNA
smart pools. Cells were fixed, stained with Hoechst dye, and analyzed. See
Supplemental Experimental Procedures.
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six figures, and seven tables and can be found with this article online at
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